Michael Heffernan
Founder presso COLLEGIUM PHARMACEUTICAL, INC.
Patrimonio netto: 2 M $ in data 29/02/2024
Profilo
Founder of 5 different companies, which include: Collegium Pharmaceutical, Inc., Avenge Bio, Inc. and PreCision Dermatology, Inc. Michael Thomas Heffernan is an entrepreneur and businessperson who has been the head of 10 different companies and is Chairman of Collegium Pharmaceutical, Inc. (which he founded in 2002), Chairman of NMD Pharma A, Chairman for Indalo Therapeutics, Inc. and President, Chief Executive Officer & Director at Avenge Bio, Inc. (which he founded in 2019).
Mr. Heffernan is also on the board of Trevi Therapeutics, Inc., Synlogic, Inc., K36 Therapeutics, Inc. and Biohaven Ltd.
In his past career Mr. Heffernan was Chairman for Astellas Institute for Regenerative Medicine, Principal at Eli Lilly & Co., Chairman for Veloxis Pharmaceuticals A, Chairman, President & Chief Executive Officer at Phymatrix Corp., Chairman of CTx Operations, Inc., President & Chief Executive Officer at Clinical Studies Ltd.
(he founded the company in 1995), President & Chief Executive Officer for Onset Dermatologics LLC (he founded the company in 2005) and Director at PreCision Dermatology, Inc.
Mr. Heffernan received an undergraduate degree from the University of Connecticut.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
18/05/2023 | 37 815 ( 0.12% ) | 1 M $ | 29/02/2024 | |
BIOHAVEN LTD.
0.02% | 02/05/2023 | 15 178 ( 0.02% ) | 730 669 $ | 29/02/2024 |
TREVI THERAPEUTICS, INC.
0.01% | 28/06/2023 | 6 351 ( 0.01% ) | 18 545 $ | 29/02/2024 |
SYNLOGIC INC
-.--% | 18/08/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Posizioni attive di Michael Heffernan
Società | Posizione | Inizio |
---|---|---|
COLLEGIUM PHARMACEUTICAL, INC. | Founder | 01/01/2002 |
TREVI THERAPEUTICS, INC. | Director/Board Member | 01/02/2017 |
SYNLOGIC, INC. | Director/Board Member | 08/12/2020 |
BIOHAVEN LTD. | Director/Board Member | 28/09/2022 |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Chairman | 03/01/2023 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Founder | 01/03/2019 |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Chairman | 17/12/2019 |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Director/Board Member | - |
Precedenti posizioni note di Michael Heffernan
Società | Posizione | Fine |
---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 03/10/2022 |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Michael Heffernan
University of Connecticut | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 6 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
AKEBIA THERAPEUTICS, INC. | Health Technology |
TREVI THERAPEUTICS, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
BIOHAVEN LTD. | Health Technology |
Aziende private | 16 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
TYRX, Inc.
TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
Cornerstone BioPharma, Inc.
Cornerstone BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone BioPharma, Inc. develops and commercializes biopharmaceutical products for respiratory disorders. Its products include AlleRx, Balacet, Deconsal, and Spectracef. The company was founded in March 2004 by Craig A. Collard, Chenyqua Baldwin, and Steven Lutz and is headquartered in Cary, NC | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | Health Technology |
Clinical Studies Ltd.
Clinical Studies Ltd. Miscellaneous Commercial ServicesCommercial Services Clinical Studies Ltd. provides multi-therapeutic, Phase I-IV clinical research studies. The company is based in Providence, RI. The company was founded by Michael Thomas Heffernan. Clinical Studies was acquired by Comprehensive NeuroScience, Inc. from Innovative Clinical Solutions Ltd. on February 08, 2002. | Commercial Services |
Phymatrix Corp. | Health Services |
Astellas Institute for Regenerative Medicine
Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
Cornerstone Therapeutics, Inc.
Cornerstone Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC. | Health Technology |
Onset Dermatologics LLC
Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | Health Technology |
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Health Technology |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Health Technology |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Health Technology |